Cargando…
High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
Cancer genome instability leads to accumulation of mutations which may result into tumor-specific mutated “neoantigens”, not be affected by central T-cell tolerance. Such neoantigens are considered the optimal target for the patient’s anti-tumor T cell immunity as well as for personalized cancer imm...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966682/ https://www.ncbi.nlm.nih.gov/pubmed/31756926 http://dx.doi.org/10.3390/cancers11121824 |
_version_ | 1783488793061359616 |
---|---|
author | Mauriello, Angela Zeuli, Roberta Cavalluzzo, Beatrice Petrizzo, Annacarmen Tornesello, Maria Lina Buonaguro, Franco M. Ceccarelli, Michele Tagliamonte, Maria Buonaguro, Luigi |
author_facet | Mauriello, Angela Zeuli, Roberta Cavalluzzo, Beatrice Petrizzo, Annacarmen Tornesello, Maria Lina Buonaguro, Franco M. Ceccarelli, Michele Tagliamonte, Maria Buonaguro, Luigi |
author_sort | Mauriello, Angela |
collection | PubMed |
description | Cancer genome instability leads to accumulation of mutations which may result into tumor-specific mutated “neoantigens”, not be affected by central T-cell tolerance. Such neoantigens are considered the optimal target for the patient’s anti-tumor T cell immunity as well as for personalized cancer immunotherapy strategies. However, only a minor fraction of predicted neoantigens are relevant to the clinical outcome. In the present study, a prediction algorithm was applied using datasets of RNA sequencing from all 377 Hepatocellular carcinoma (HCC) patients available at The Cancer Genome Atlas (TCGA), to predict neoantigens to be presented by each patient’s autologous HLA molecules. Correlation with patients’ survival was performed on the 115 samples for whom the exact date of death was known. A total of 30 samples were used for the training set, and 85 samples were used for the validation sets. Neither the somatic mutations nor the number nor the quality of the predicted neoantigens correlate as single parameter with survival of HCC patients who do not undergo immunotherapy treatment. Furthermore, the preferential presentation of such neoantigens in the context of one of the major histocompatibility complex MHC class I molecules does not have an impact on the survival. On the contrary, the expression of Granzyme A (GZMA) is significantly correlated with survival and, in the context of high GZMA, a direct correlation between number and quality of neoantigens with survival is observed. This is in striking contrast to results described in cancer patients undergoing immunotherapy, in which a strong correlation between Tumor Mutational Burden (TMB), number of predicted neoantigens and survival has been reported. |
format | Online Article Text |
id | pubmed-6966682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69666822020-02-04 High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy Mauriello, Angela Zeuli, Roberta Cavalluzzo, Beatrice Petrizzo, Annacarmen Tornesello, Maria Lina Buonaguro, Franco M. Ceccarelli, Michele Tagliamonte, Maria Buonaguro, Luigi Cancers (Basel) Article Cancer genome instability leads to accumulation of mutations which may result into tumor-specific mutated “neoantigens”, not be affected by central T-cell tolerance. Such neoantigens are considered the optimal target for the patient’s anti-tumor T cell immunity as well as for personalized cancer immunotherapy strategies. However, only a minor fraction of predicted neoantigens are relevant to the clinical outcome. In the present study, a prediction algorithm was applied using datasets of RNA sequencing from all 377 Hepatocellular carcinoma (HCC) patients available at The Cancer Genome Atlas (TCGA), to predict neoantigens to be presented by each patient’s autologous HLA molecules. Correlation with patients’ survival was performed on the 115 samples for whom the exact date of death was known. A total of 30 samples were used for the training set, and 85 samples were used for the validation sets. Neither the somatic mutations nor the number nor the quality of the predicted neoantigens correlate as single parameter with survival of HCC patients who do not undergo immunotherapy treatment. Furthermore, the preferential presentation of such neoantigens in the context of one of the major histocompatibility complex MHC class I molecules does not have an impact on the survival. On the contrary, the expression of Granzyme A (GZMA) is significantly correlated with survival and, in the context of high GZMA, a direct correlation between number and quality of neoantigens with survival is observed. This is in striking contrast to results described in cancer patients undergoing immunotherapy, in which a strong correlation between Tumor Mutational Burden (TMB), number of predicted neoantigens and survival has been reported. MDPI 2019-11-20 /pmc/articles/PMC6966682/ /pubmed/31756926 http://dx.doi.org/10.3390/cancers11121824 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mauriello, Angela Zeuli, Roberta Cavalluzzo, Beatrice Petrizzo, Annacarmen Tornesello, Maria Lina Buonaguro, Franco M. Ceccarelli, Michele Tagliamonte, Maria Buonaguro, Luigi High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy |
title | High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy |
title_full | High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy |
title_fullStr | High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy |
title_full_unstemmed | High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy |
title_short | High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy |
title_sort | high somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in hcc patients not undergoing immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966682/ https://www.ncbi.nlm.nih.gov/pubmed/31756926 http://dx.doi.org/10.3390/cancers11121824 |
work_keys_str_mv | AT maurielloangela highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy AT zeuliroberta highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy AT cavalluzzobeatrice highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy AT petrizzoannacarmen highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy AT tornesellomarialina highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy AT buonagurofrancom highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy AT ceccarellimichele highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy AT tagliamontemaria highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy AT buonaguroluigi highsomaticmutationandneoantigenburdendonotcorrelatewithdecreasedprogressionfreesurvivalinhccpatientsnotundergoingimmunotherapy |